Caribou Biosciences (CRBU) Tax Provisions (2020 - 2021)
Caribou Biosciences (CRBU) reported Tax Provisions of $321000.0 for Q4 2021, up 190.68% year-over-year from $110431.5 in Q4 2020, and up 190.68% on a QoQ basis from -$354000.0 in Q4 2020.
Caribou Biosciences (CRBU) has 2 years of Tax Provisions data on file, last reported at $321000.0 in Q4 2021.
- Quarterly Tax Provisions rose 190.68% year-over-year to $321000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $321000.0 (up 117.65% YoY) and the FY2025 annual result came in at -$550000.0, down 6011.11% from the prior year.
- Tax Provisions rose to $321000.0 in Q4 2021 per CRBU's latest filing, from -$354000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $321000.0 in Q4 2021 and bottomed at -$1.2 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 321,000.00 |
| Dec 31, 2020 | -354,000.00 |
| Sep 30, 2020 | -213,000.00 |
| Jun 30, 2020 | -50,000.00 |
| Mar 31, 2020 | -1.20 Mn |